Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label, single-arm phase II study of vemurafenib in metastatic melanoma with brain metastases
2011-000954-46Phase 2Completed
- Sponsor
- Roche
- Start
- May 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of vemurafenib in melanoma, sponsored by Roche. Primary endpoint: Best Overall Response Rate (BORR) in previously untreated brain metastases. Started May 2011; status: completed.
02
Drugs
vemurafenib
03
Conditions
melanoma
Beyond the preview
Go deeper on 2011-000954-46.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-000954-46.